IRIDEX Corporation (IRIX) Earnings
IRIDEX Corporation is expected to report next earnings on November 17, 2026 (in NaN days), with a consensus EPS estimate of $-0.04. IRIX has beaten EPS estimates in 6 of its last 12 reported quarters (average surprise -114.9% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 18, 2026 | $-0.01 | $-0.07 | -600.0% | $13M | -7.5% |
| May 19, 2026 | $-0.07 | $-0.03 | +57.1% | $12M | -0.9% |
| Mar 26, 2026 | $-0.02 | $-0.01 | +50.0% | $15M | -0.1% |
| Aug 12, 2025 | $-0.09 | $-0.06 | +33.3% | $14M | +3.6% |
| Mar 27, 2025 | $-0.05 | $-0.05 | +0.0% | $13M | -0.8% |
| Aug 8, 2024 | $-0.12 | $-0.16 | -33.3% | $13M | +0.2% |
| May 14, 2024 | $-0.12 | $-0.21 | -75.0% | $12M | -2.0% |
| Nov 14, 2023 | $-0.13 | $-0.11 | +15.4% | $13M | -10.6% |
| Aug 10, 2023 | $-0.11 | $-0.17 | -54.5% | $13M | -9.7% |
| May 11, 2023 | $-0.12 | $-0.13 | -8.3% | $14M | -4.5% |
| Mar 9, 2023 | $-0.11 | $-0.07 | +36.4% | $15M | +0.2% |
| Nov 10, 2022 | $-0.15 | $-0.11 | +26.7% | $15M | +5.5% |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q2 FY2026 · August 18, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Financial and Operational Transformation: Iridex reached a key inflection point, delivering positive operating cash flow in Q2 2026, demonstrating the success of two years of cost structure transformation, improved working capital management, and operational discipline. Operating expenses were reduced 5% year-over-year to $5.3 million, driven by lower general and administrative costs from ongoing efficiency initiatives. The company has begun relocating its headquarters, a long-planned cost-cutting step to align infrastructure with future growth. As part of the transition, the company is building safety stock inventory to maintain supply continuity and protect international distributor revenue during global registration blackout periods, which temporarily impacts cash on hand through 2026 but will become a cash tailwind in 2027 as inventory is worked down. The multi-year transition of production to lower-cost third-party contract manufacturers is progressing, with both the headquarters move and manufacturing shift expected to drive gross margin improvements in 2027. - Glaucoma Segment Commercial Performance: The glaucoma franchise delivered solid probe-led growth, with 35% year-over-year probe volume growth and 19% year-over-year Cyclo G6 product family revenue growth across all operating regions. Growth is driven by three core initiatives: 1) Targeted physician engagement via the MedScout tool, which focuses on increasing utilization among moderate-utilization existing accounts and driving adoption among high-volume practices not yet using micropulse therapy; 2) Continued reimbursement tailwinds from 2025 Medicare Local Coverage Determinations (LCDs), which support broader adoption of the non-incisional, repeatable micropulse therapy; 3) Domestic average selling price (ASP) increases for both probes and systems, reflecting the perceived clinical value of the G6 platform. Internationally, the UK clinical registry for G6 is progressing well, with strong clinical community engagement; positive registry data is expected to support expanded reimbursement that will drive higher adoption and probe volumes across Europe. German and Austrian operations continue to reclaim business from the former distributor, though competition for new console placements persists. Asian distributors placed larger stocking orders ahead of the upcoming Japanese business transition, boosting segment sales in the quarter. - Retina Segment Commercial Performance: The segment faced temporary market dynamics and operational execution challenges in the quarter, but underlying customer demand remains strong. Domestically, Iridex added endoprobe handpieces to its existing iProGPO group purchasing agreement, expanding access to over 4,300 member practices, ambulatory surgery centers, and hospitals, creating a new growth lever for the domestic retina business. Internationally, results were mixed: Pascal MDR approval in Europe is expected in H1 2027, which will unlock meaningful demand after certification; Chinese sell-through was impacted by regulatory delays and distributor inventory digestion, with normalization expected over coming quarters; sales in Latin America and Canada have resumed after prior challenges, with continued growth expected in H2 2026. The company's long-term retina priorities include advancing the domestic Pascal upgrade cycle, expanding Pascal's international footprint, and securing regulatory clearances for next-generation platforms to leverage the company's global distribution network.
Guidance
- Management reaffirmed its full year 2026 revenue guidance range of $51 million to $53 million. Excluding excluded Middle East region revenue, this guidance represents 1% to 5% pro forma year-over-year revenue growth compared to 2025. - Management also reaffirmed its full year 2026 adjusted operating expenses guidance (which includes depreciation, amortization, and stock-based compensation) at a range of $19 million to $19.5 million. - Management expects sequential quarterly cash generation growth through the remainder of 2026, after accounting for temporary working capital investment in safety stock inventory for the headquarters transition. - Management expects low single-digit year-over-year growth for the Retina segment in H2 2026, and confirms that Q4 2026 will again be the strongest quarter of the year for revenue, as is historical precedent.
Segment performance
Iridex generated total Q2 2026 revenue of $12.6 million, a 7% year-over-year decline from $13.6 million in Q2 2025. The Glaucoma segment, specifically the Cyclo G6 product family, generated $3.9 million in revenue (31% of total Q2 2026 revenue), representing 19% year-over-year growth. Cyclo-G6 probe volume reached 17,700 units, a 35% year-over-year increase, driven by higher adoption and utilization of the G6 platform. The Retina segment generated $6.5 million in revenue (51.6% of total Q2 2026 revenue), a 18.75% year-over-year decline from $8.0 million in Q2 2025. The decline was attributed to temporary international commercial transitions and regulatory-related factors, while underlying product demand remained robust. Other revenue was flat year-over-year at $2.2 million (17.5% of total Q2 2026 revenue).
Risks & headwinds
- The headquarters relocation and associated product re-registration process requires global registration blackout periods, which create supply chain continuity risk. The company's proactive safety stock build mitigates this risk but temporarily reduces cash on hand through 2026. - Variability in international ordering timing creates near-term revenue choppiness across global regions, with deferred backlog shifting to future quarters and large current stocking orders leading to expected sequential declines in some regions in subsequent quarters. - Retina segment performance continues to be impacted by temporary headwinds from Middle East market disruption, Chinese regulatory delays, and inventory management tied to the headquarters transition. The ongoing competitive pressure for new G6 console placements in the GmbH region also creates headwinds for glaucoma system sales. - All forward-looking statements are subject to material risks and uncertainties that could cause actual results to differ materially from current expectations, as detailed in the company's most recent SEC filings.
Analyst Q&A
Q: Given the temporary headwinds facing the Retina segment, does management expect full year Retina to grow year over year, and specifically to grow in H2 2026 compared to H2 2025? /
A: Management confirms it expects low single-digit year-over-year growth for Retina in H2 2026. Tailwinds expected to drive this growth include expanding addressable market from upcoming international regulatory approvals for the flagship Pascal product, and upcoming domestic momentum from the American Academy of Ophthalmology meeting and associated annual capital equipment promotion programs that drive customer engagement. The H2 growth outlook accounts for existing headwinds from Middle East disruption, Chinese sell-through delays, and inventory management tied to the headquarters relocation blackout periods.
Q: Q2 2026 Cyclo G6 probe volume of 17,700 units was far higher than previous quarters. Is this due to customer inventory build, and will volumes normalize or hold at this new level in H2? /
A: There was some temporary lumpiness from pre-order stocking by distributors, most notably in Japan and Europe, to cover the upcoming registration blackout period for the headquarters move. Even after backing out this pre-order volume, underlying organic growth was still over 15% year-over-year, and management expects low double-digit probe growth in H2 2026, which it views as a strong sustainable performance.
Q: Q2 2026 G6 system placements of 18 units were lower than the prior year's 35 units. Should we expect system sales to rebound higher in H2 2026? /
A: Management confirms system sales will be meaningfully higher in H2 2026, consistent with the historical trend of Q4 being the company's largest quarter for both system and overall sales. The Q2 slowdown was driven primarily by order timing delays in Europe, Middle East, and Africa, as the market waits for UK registry data and expanded reimbursement approval that will drive new console placements. Those headwinds are expected to ease in the second half of the year.